Speakers
Anna Smith
CTO, US Medical Affairs
Precision Oncology
Christy Russell
Vice President, US Medical Affairs
Precision Oncology
Dates
Thursday,
3:00 PM PT / 6:00 PM ET
Join Us for a Webinar
Highlights of SABCS 2021
Join Dr. Christy Russell (VP, US Medical Affairs at Exact Sciences) as she reviews new data presented at SABCS 2021 and their implications for clinical management of breast cancer patients. Included will be an in-depth discussion of the latest data from the landmark RxPONDER trial. Dr. Russell will be available for a live Q&A following the presentation
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation
RxPONDER Clinical Trial Key Findings1
At SABCS 2020, Kevin Kalinsky, MD presented early RxPONDER data.
- The majority of HR+, HER2-, N1 patients can be spared chemotherapy when decisions are guided with the Oncotype DX test
- Postmenopausal women with 1-3 positive nodes and Recurrence Score result 0-25 can forgo adjuvant chemotherapy regardless of clinical pathological parameters
- Premenopausal women with 1-3 positive nodes and Recurrence Score result 0-25 significantly benefit from chemotherapy
RxPONDER study results are expected to be practice-changing for N1 HR+, HER2-, early breast cancer patients
-
References